185 related articles for article (PubMed ID: 28919454)
21. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
22. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer.
Nicholson S; Bomphray CC; Thomas H; McIndoe A; Barton D; Gore M; George AJ
Cancer Immunol Immunother; 2004 Sep; 53(9):809-16. PubMed ID: 15127236
[TBL] [Abstract][Full Text] [Related]
25. Biologic and immunologic therapies for ovarian cancer.
Berek JS; Schultes BC; Nicodemus CF
J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
[TBL] [Abstract][Full Text] [Related]
26. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
[TBL] [Abstract][Full Text] [Related]
27. Lymphocyte activation as cytokine gene expression and secretion is related to the porcine reproductive and respiratory syndrome virus (PRRSV) isolate after in vitro homologous and heterologous recall of peripheral blood mononuclear cells (PBMC) from pigs vaccinated and exposed to natural infection.
Ferrari L; Martelli P; Saleri R; De Angelis E; Cavalli V; Bresaola M; Benetti M; Borghetti P
Vet Immunol Immunopathol; 2013 Feb; 151(3-4):193-206. PubMed ID: 23228653
[TBL] [Abstract][Full Text] [Related]
28. Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.
Miyai M; Eikawa S; Hosoi A; Iino T; Matsushita H; Isobe M; Uenaka A; Udono H; Nakajima J; Nakayama E; Kakimi K
PLoS One; 2015; 10(8):e0136086. PubMed ID: 26291626
[TBL] [Abstract][Full Text] [Related]
29. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
30. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
[TBL] [Abstract][Full Text] [Related]
31. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
Gorse GJ; Simionescu RE; Patel GB
Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
[TBL] [Abstract][Full Text] [Related]
32. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
33. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
[TBL] [Abstract][Full Text] [Related]
34. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
[TBL] [Abstract][Full Text] [Related]
35. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer.
Möbus VJ; Baum RP; Bolle M; Kreienberg R; Noujaim AA; Schultes BC; Nicodemus CF
Am J Obstet Gynecol; 2003 Jul; 189(1):28-36. PubMed ID: 12861134
[TBL] [Abstract][Full Text] [Related]
36. [In vivo study of antitumor immune responses induced by anti-idiotypic minibody vaccine of ovarian cancer].
Chang XH; Cui H; Feng J; Yang WL; Li Y; Fu TY
Ai Zheng; 2004 Jul; 23(7):777-81. PubMed ID: 15248911
[TBL] [Abstract][Full Text] [Related]
37. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay.
Schultes BC; Whiteside TL
J Immunol Methods; 2003 Aug; 279(1-2):1-15. PubMed ID: 12969543
[TBL] [Abstract][Full Text] [Related]
39. Construction and expression of a single chain antibody mimicing human ovarian cancer antigen CA125.
Li AD; Li Z; Wang YH; Zhang YM; Ma J
Cell Mol Immunol; 2006 Feb; 3(1):59-62. PubMed ID: 16549051
[TBL] [Abstract][Full Text] [Related]
40. Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.
Drugs R D; 2006; 7(6):379-83. PubMed ID: 17073521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
